GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Short-Term Debt

CG Oncology (CG Oncology) Short-Term Debt : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Short-Term Debt?

CG Oncology's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

CG Oncology's annual Short-Term Debt increased from Dec. 2021 ($2.94 Mil) to Dec. 2022 ($8.97 Mil) but then declined from Dec. 2022 ($8.97 Mil) to Dec. 2023 ($0.00 Mil).

CG Oncology Short-Term Debt Historical Data

The historical data trend for CG Oncology's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Short-Term Debt Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23
Short-Term Debt
2.94 8.97 -

CG Oncology Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Short-Term Debt Get a 7-Day Free Trial 8.97 - - - -

CG Oncology Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

CG Oncology Short-Term Debt Related Terms

Thank you for viewing the detailed overview of CG Oncology's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

CG Oncology (CG Oncology) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Short-Term Debt
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.

CG Oncology (CG Oncology) Headlines

From GuruFocus

CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024

By Marketwired • 04-24-2024